These findings reflect disproportional reporting patterns rather than causal or protective effects and should be interpreted cautiously given inherent FAERS limitations, including missing clinical details and lack of denominator data. The results are hypothesis-generating and warrant further investigation using real-world clinical datasets to better characterize renal safety across immunosuppressant combinations.
Urawa et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: